Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) EPS (Basic) (2016 - 2025)

Tg Therapeutics has reported EPS (Basic) over the past 10 years, most recently at $0.2 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.2 for Q4 2025, up 25.0% from a year ago — trailing twelve months through Dec 2025 was $3.11 (up 1729.41% YoY), and the annual figure for FY2025 was $3.1, up 1837.5%.
  • EPS (Basic) for Q4 2025 was $0.2 at Tg Therapeutics, down from $2.69 in the prior quarter.
  • Over the last five years, EPS (Basic) for TGTX hit a ceiling of $2.69 in Q3 2025 and a floor of -$0.7 in Q4 2021.
  • Median EPS (Basic) over the past 5 years was -$0.18 (2023), compared with a mean of -$0.05.
  • Biggest five-year swings in EPS (Basic): crashed 96.25% in 2024 and later surged 8866.67% in 2025.
  • Tg Therapeutics' EPS (Basic) stood at -$0.7 in 2021, then grew by 18.57% to -$0.57 in 2022, then surged by 82.46% to -$0.1 in 2023, then skyrocketed by 260.0% to $0.16 in 2024, then grew by 25.0% to $0.2 in 2025.
  • The last three reported values for EPS (Basic) were $0.2 (Q4 2025), $2.69 (Q3 2025), and $0.19 (Q2 2025) per Business Quant data.